Per Lindnér

2.2k total citations
80 papers, 1.6k citations indexed

About

Per Lindnér is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Per Lindnér has authored 80 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 21 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Per Lindnér's work include Organ Transplantation Techniques and Outcomes (15 papers), Ocular Oncology and Treatments (14 papers) and Renal Transplantation Outcomes and Treatments (13 papers). Per Lindnér is often cited by papers focused on Organ Transplantation Techniques and Outcomes (15 papers), Ocular Oncology and Treatments (14 papers) and Renal Transplantation Outcomes and Treatments (13 papers). Per Lindnér collaborates with scholars based in Sweden, Denmark and Australia. Per Lindnér's co-authors include Magnus Rizell, Roger Olofsson Bagge, Peter Naredi, Christian Cahlin, Jan Mattsson, Michael Olausson, Peter Kam, John F. Thompson, Larsolof Hafström and Anna Doubrovsky and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Per Lindnér

79 papers receiving 1.6k citations

Peers

Per Lindnér
Ami B. Patel United States
Lidia Puzzo Italy
Haifeng Xu China
Stefania Marsili Italy
Masamichi Sugimoto Japan
Guomin Jiang China
Stefanie Koidl Germany
Yubin Kang United States
Xiaoyong Huang China
Masahiro Ohira Japan
Ami B. Patel United States
Per Lindnér
Citations per year, relative to Per Lindnér Per Lindnér (= 1×) peers Ami B. Patel

Countries citing papers authored by Per Lindnér

Since Specialization
Citations

This map shows the geographic impact of Per Lindnér's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Lindnér with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Lindnér more than expected).

Fields of papers citing papers by Per Lindnér

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Lindnér. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Lindnér. The network helps show where Per Lindnér may publish in the future.

Co-authorship network of co-authors of Per Lindnér

This figure shows the co-authorship network connecting the top 25 collaborators of Per Lindnér. A scholar is included among the top collaborators of Per Lindnér based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Lindnér. Per Lindnér is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
All‐Eriksson, Charlotta, Christian Cahlin, Nils Elander, et al.. (2024). Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial).. Journal of Clinical Oncology. 42(16_suppl). 9532–9532.
2.
Bagge, Roger Olofsson, Ana Carneiro, Hafdís T. Helgadóttir, et al.. (2024). A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial). ESMO Open. 9(7). 103623–103623. 4 indexed citations
3.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).. Journal of Clinical Oncology. 41(17_suppl). LBA9512–LBA9512. 1 indexed citations
4.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Journal of Clinical Oncology. 41(16). 3042–3050. 33 indexed citations
5.
6.
Ekberg, Jana, Seema Baid‐Agrawal, Bente Jespersen, et al.. (2021). A Randomized Controlled Trial on Safety of Steroid Avoidance in Immunologically Low-Risk Kidney Transplant Recipients. Kidney International Reports. 7(2). 259–269. 8 indexed citations
7.
Zur‐Mühlen, Bengt von, Bo‐Göran Ericzon, Carin Wallquist, et al.. (2021). COVID-19 in solid organ transplant recipients: A national cohort study from Sweden. American Journal of Transplantation. 21(8). 2762–2773. 27 indexed citations
8.
Rizell, Magnus, et al.. (2020). Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. Case Reports in Oncology. 13(1). 478–484. 22 indexed citations
9.
Eilard, Malin Sternby, Mats Andersson, Peter Naredi, et al.. (2019). A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer. 19(1). 568–568. 22 indexed citations
10.
Hansson, Christoffer, Malin Sternby Eilard, Christian Cahlin, et al.. (2015). Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma. Journal of Visualized Experiments. 52490–52490. 18 indexed citations
11.
Bagge, Roger Olofsson, Lars Ny, Malin Sternby Eilard, et al.. (2014). Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials. 15(1). 317–317. 29 indexed citations
12.
Eldh, Maria, Roger Olofsson Bagge, Cecilia Lässer, et al.. (2014). MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer. 14(1). 962–962. 90 indexed citations
13.
Rizell, Magnus, Mats Andersson, Christian Cahlin, et al.. (2008). Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. International Journal of Clinical Oncology. 13(1). 66–70. 109 indexed citations
14.
Rizell, Magnus, et al.. (2008). Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Research. 18(2). 120–126. 30 indexed citations
15.
Lindnér, Per, John F. Thompson, Johannes H. W. de Wilt, Marjorie H. Colman, & Peter Kam. (2004). Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. European Journal of Surgical Oncology. 30(4). 433–439. 31 indexed citations
16.
Falkenberg, Mårten, Tom Björnheden, Per Lindnér, & Bo Risberg. (1998). Co-Localization of Fibrinolytic Activators and Inhibitors with Macrophages in Atherosclerotic Vessels. Cardiovascular Pathology. 7(4). 223–231. 5 indexed citations
17.
Hafström, Larsolof, Stig B. Holmberg, Peter Naredi, et al.. (1994). Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surgical Oncology. 3(2). 103–108. 63 indexed citations
18.
Hafström, Larsolof, Boel Engarås, Stig B. Holmberg, et al.. (1994). Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial. Cancer. 74(10). 2749–2756. 26 indexed citations
19.
Westin, Thomas, B. Soussi, J. P. Idstrom, et al.. (1993). Energetics of nutrition and polyamine-related tumour growth alterations in experimental cancer. British Journal of Cancer. 68(4). 662–667. 3 indexed citations
20.
Lindnér, Per, Dennis D. Heath, David R. Shalinsky, et al.. (1993). Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. Surgical Oncology. 2(2). 105–112. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ami B. Patel Breakdown of academic impact, for papers by Lidia Puzzo Breakdown of academic impact, for papers by Haifeng Xu Breakdown of academic impact, for papers by Stefania Marsili Breakdown of academic impact, for papers by Masamichi Sugimoto Breakdown of academic impact, for papers by Guomin Jiang Breakdown of academic impact, for papers by Stefanie Koidl Breakdown of academic impact, for papers by Yubin Kang Breakdown of academic impact, for papers by Xiaoyong Huang Breakdown of academic impact, for papers by Masahiro Ohira
Rankless by CCL
2026